150MO Safety results from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis
Titel:
150MO Safety results from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis
Auteur:
Chan, S.L. Kudo, M. Sangro, B. Kelley, R.K. Kim, J.H. Van Binh, P. Hong, J.Y. Waldschmidt, D.T. Marino, D. Gerolami, R. Li, Q. Nakamura, H. Sun, P. Baur, B. Rimassa, L.